Biology of Blood and Marrow Transplantation
Volume 11, Issue 7 , Pages 551-557 , July 2005

Sirolimus and Thrombotic Microangiopathy after Allogeneic Hematopoietic Stem Cell Transplantation

  • Corey Cutler

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, Massachusetts
    • Corresponding Author InformationCorrespondence and reprint requests: Corey Cutler, MD, MPH, FRCP(C), Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney St., Boston, MA 02115
    • ,
  • N. Lynn Henry

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, Massachusetts
    • ,
  • Colm Magee

      Affiliations

    • Department of Nephrology, Brigham and Women’s Hospital, Boston, Massachusetts
    • ,
  • Shuli Li

      Affiliations

    • Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, Massachusetts
    • ,
  • Haesook T. Kim

      Affiliations

    • Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, Massachusetts
    • ,
  • Edwin Alyea

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, Massachusetts
    • ,
  • Vincent Ho

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, Massachusetts
    • ,
  • Stephanie J. Lee

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, Massachusetts
    • ,
  • Robert Soiffer

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, Massachusetts
    • ,
  • Joseph H. Antin

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, Massachusetts

Received 21 February 2005 ,Accepted 21 April 2005.

  • Image Result

    Survival analysis of patients from the time of thrombotic microangiopathy diagnosis. Survival in the sirolimus cohort was superior to that of the nonsirolimus cohort (58.3% versus 11.1%; P = .02).

    Survival analysis of patients from the time of thrombotic microangiopathy diagnosis. Survival in the sirolimus cohort was superior to that of the nonsirolimus cohort (58.3% versus 11.1%; P = .02).

 C.C. and N.L.H. contributed equally to this article.

PII: S1083-8791(05)00263-6

doi: 10.1016/j.bbmt.2005.04.007

Biology of Blood and Marrow Transplantation
Volume 11, Issue 7 , Pages 551-557 , July 2005

Article Tools

* Image Usage & Resolution